Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3/9/26 16:07 | 3/5/26 | XNCR | Health | Drug | Pharmaceutical Preparations | Desjarlais John R | CA | O | SVP,CSO | 5 | S.dm | -2,322 | 13.85 | 0 | -168 | 270 | D | |||||||||||||||
3/9/26 16:06 | 3/5/26 | XNCR | Health | Drug | Pharmaceutical Preparations | Eckert Celia | CA | O | SVP,GC | 2 | S.dm | -74 | 11.33 | 0 | -7 | 82 | D | |||||||||||||||
3/9/26 16:06 | 3/5/26 | XNCR | Health | Drug | Pharmaceutical Preparations | Cornelissen Bart Jan | CA | O | SVP,CFO | 1 | S | -28 | 11.25 | 0 | -3 | 79 | D | |||||||||||||||
3/9/26 16:06 | 3/5/26 | XNCR | Health | Drug | Pharmaceutical Preparations | Dahiyat Bassil I | CA | DO | P,CEO | 4 | S.dm | -3,681 | 13.76 | 0 | -268 | 568 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |